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doi:10.1016/j.ejvs.2011.02.019Abstract Objectives: Despite limited scientific evidence for the effectiveness of invasive treat-
ment for intermittent claudication (IC), revascularisation procedures for IC are increasingly often per-
formed in Sweden. This randomised controlled trial compares the outcome after 2 years of primary
invasive (INV) versus primary non-invasive (NON) treatment strategies in unselected IC patients.
Materials/Methods: Basedonarterial duplexandclinicalexamination, ICpatientswere randomised to
INV (endovascular and/or surgical, nZ 100) or NON (nZ 101). NON patients could request invasive
treatment if they deteriorated during follow-up. Primary outcomewasmaximal walking performance
(MWP) on graded treadmill test at 2 years and secondary outcomes included health-related quality of
life (HRQL), assessed with Short Form (36) Health Survey (SF-36).
Results: MWPwas not significantly (pZ 0.104) improved in the INV versus the NON group. Two SF-36
physical subscales, Bodily Pain (p< 0.01) and Role Physical (p< 0.05) improved significantlymore in
the INV versus the NON group. Therewere 7% crossovers against the study protocol in the INV group.
Conclusions: Although invasive treatment did not show any significant advantage regarding MWP,
the HRQL improvements associated with invasive treatment tentatively suggest secondary benefits
of this regimen.On the other hand, a primary non-invasive treatment strategy seems to be accepted
by most IC patients.
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Randomised Trial in Intermittent Claudication 221Intermittent claudication (IC), occurring in 7% of individ-
uals over the age of 60 years in Sweden,1 is the most
frequent symptom of peripheral arterial disease (PAD).2 IC
may cause considerable functional impairment affecting
important aspects of health-related quality of life (HRQL).
The prognosis for the extremity is benign,3 and treatment
therefore aims at improved walking performance and
HRQL. Most IC patients seeking medical attention are
offered risk-factor management and exercise training.
Regarding walking performance, there is limited evidence
for the benefit of adding invasive treatment.4 In addition,
IC patients have a high prevalence of coronary artery
disease,5 leading to a significant risk of ischaemic cardiac
events, if invasive procedures are undertaken.6 In spite of
uncertain merits and potential risks, 37% of all open
surgical and/or endovascular procedures for PAD in Sweden
are performed for IC.7 Most controlled studies of invasive
treatment for IC are performed on selected patients, with
lesions in certain arterial segments, suitable for
angioplasty.
The generally accepted first-line treatment strategy is
medical treatment and exercise training. In our clinical
routine, patients referred for IC undergo arterial duplex
and a clinical examination and, thereafter, usually
a primary non-invasive, or, in some cases, an invasive,
treatment strategy is chosen. The aim of this randomised
controlled study was to test the hypothesis that a primary
invasive surgical/endovascular treatment strategy versus
a primary non-invasive strategy improves maximal walking
performance (MWP) in unselected patients receiving best
medical treatment (BMT) and non-supervised exercise
training.Materials and MethodsStudy population, general design and
inclusion/exclusion criteria
This prospective, randomised, controlled trial during an
initial phase started as a regional multicentre study coor-
dinated at the Vascular Surgical Department at Sahlgrenska
University Hospital, Gothenburg, Sweden. During the initial
period, 20 of the patients were included and treated in two
other hospitals. For logistic reasons, the study subsequently
became a single-centre study at the Sahlgrenska University
Hospital.
Patients with IC symptoms >6 months were first inter-
viewed and examined by a senior vascular surgeon, who
established the diagnosis and assessed risk at the outpa-
tient clinic. All referred IC patients were screened for
inclusion in the present study. Patients 85 years, or with
incorrect diagnosis and/or other disorders limiting walking
performance were excluded as were patients with two or
more previously occluded vascular reconstructions.
Employees unable to work because of IC and patients with
subcritical ischaemia and/or with aortic thrombosis were
offered invasive treatment. Patients only seeking advice
were offered non-invasive treatment.
The remaining IC patients were eligible for inclusion.
These patients underwent duplex ultrasound of theaorto-iliac and femoroepoplitaeal arterial segments and
a treadmill test.
Eligible patients giving informed consent, and who on
duplex ultrasound from the infrarenal aorta to the tibio-
peroneal trunk had treatable lesions in or proximal to the
tibioperoneal trunk, were randomised to invasive (INV) or
non-invasive treatment (NON). The NON group patients
were informed that they could request invasive therapy, if
their symptoms deteriorated during follow-up. The INV
group patients underwent risk assessment by an anaes-
thesiologist and, when needed, a cardiologist. If significant
operative risk, which was not obvious during basic risk
assessment, was detected, randomised INV patients did not
receive invasive treatment. If symptoms of IC improved
before invasive treatment, the INV patients could decline
invasive treatment. Following an arterial digital subtraction
angiography (DSA) in INV patients, invasive procedures
were applied as soon as possible.
Prospective log lists were not used. In an attempt to
estimate referral patterns for IC, the medical records of
88 consecutive IC patients referred during a 12-month
period were retrospectively reviewed at the time of final
analysis, and in a prospective cohort of 130 patients
referred for IC, rates of non-eligibility and exclusions were
estimated.
Allocation
For randomisation, we used a computerised minimisation
procedure as proposed by Pocock and Simon,8 taking 15
variables with presumed prognostic influence into account.
These variables are presented in Table 1 and were entered
into the computer as continuous or di- or trichotomised
variables as described in the table. For each new included
patient, the computerised procedure minimised differ-
ences between groups for all variables. Randomisation was
performed independently by a research nurse and reported
to the responsible vascular surgeon.
Interventions
Immediately after randomisation, patients in both groups
were assigned to risk-factor management and medical
intervention for secondary prevention. Every patient
received aspirin 75 mg daily (or ticlopidine if there was
contraindication to aspirin). Smokers were offered partici-
pation in a smoking cessation support programme and
received verbal and written information with smoking
cessation advice. Hypertension, diabetes and hyper-
lipidaemia were managed either by a general practitioner
or a specialist in internal medicine, according to contem-
porary national guidelines.
All patients received verbal training advice and
a written training programme for IC. The patients were
instructed to walk at least 1 h/day and to walk up to their
maximal claudication distance as often as possible and to
perform an additional exercise programme at home several
times a day.
In INV patients, invasive procedures were chosen by the
responsible vascular surgeon, based on DSA. In general,
aorto-iliac TASC A and B lesions were treated
Table 1 Demographics and risk factors used in the computerized minimization procedure, presented according to treatment
group. Values are given as mean  SD when applicable.
Invasive group
(n Z 100)
Non-invasive group
(n Z 101)
Age, years (range) 68 (41e84) 68 (44e84)
Gender male/female, % 62/38 64/36
Smoking habits, %, yes/ex-smoker/no 41/32/27 42/33/25
Diabetes mellitus, % 16 18
Body Mass Index (BMI) 26  3.8 26  3.4
Duration of symptoms, <1 y/1e2 y/>2 y, patients 1/48/51 0/47/54
Systolic blood pressure, mmHg 162  23 158  27
Ankle pressure, most symptomatic side, mmHg 94  27 94  31
Ankleebrachial index 0.59  0.17 0.60  0.19
Pulse in groin (symptomatic side) normal/reduced/absent, % 56/29/15 63/24/14
Maximal treadmill performance (W, watts) 66  24 67  24
S-haemoglobin (g/l) 144  14 144  13
S-cholesterol (mmol/l) 6.0  1.3 6.2  1.3
S-triglycerides (mmol/l) 2.1  1.2 2.3  2.7
S-Creatinine (mmol/l) 104  27 107  27
222 J. Nordanstig et al.endovascularly and TASC C and D lesions with surgery.
Femoropopliteal TASC A lesions were offered angioplasty,
whereas TASC BeD lesions usually were treated surgically.
For lesions in the common femoral artery, endarterectomy
with or without patch angioplasty was used.Follow-up and outcomes
Patients were followed at 1 (invasive group only), 6, 12 and
24 months by a vascular surgeon. Two specially trained
Vascular Laboratory research nurses monitored the study
and registered patient data at 6, 12 and 24 months. Primary
outcome was MWP on a graded treadmill with an increasing
workload due to progressively increasing slope (0e12) and
speed (1.5e4.5 km h1). Treadmill tests were performed at
baseline, 6, 12 and 24 months and expressed in watts (W),
based on speed, slope and body weight. Maximal walking
distance (m) on the graded treadmill was registered; and
the patients subjectively reported maximal walking
distance on a flat surface. Reasons for stopping the tread-
mill test during follow-up were registered and categorised
as maximal bearable claudication pain, general fatigue or
other causes.
Secondary outcomes included patient reported HRQL as
measured with the Medical Outcomes Study Short Form 36
(SF-36) instrument and AnkleeBrachial Index (ABI) changes.
SF-36 quantifies different aspects of HRQL in eight different
domains (MH Z Mental Health; RE Z Role Emotional;
SF Z Social Functioning; VT Z Vitality; GH Z General
Health; BP Z Bodily Pain; RP Z Role Physical; and
PF Z Physical Functioning).9Ethics committee approval
Ethical approval was obtained from the Regional Ethical
Review Board at the University of Gothenburg.Additional measurements
ABI was measured using standard techniques. The highest
value at ankle level was used. An ABI improvement of >0.1
in combination with positive clinical findings was defined as
a patent vascular reconstruction.
Cotinine, a nicotine metabolite was measured in a urine
sample at 12 and 24 months using an immunochemical
method. Nicotine use was defined as 2.0 mmol l1 nicotine
metabolites per litre.Statistical methods
A sample size of 200 evaluable IC patients with MWP < 70 W
in women and <90 W in men was chosen, based on prelimi-
nary analysis of an earlier study,14 power 80% and beta 0.05.
Main analysis was according to intention to treat, and
included all randomised patients. Statistical analysis was
performed using Statistical Package for Social Sciences
(SPSS) version 17.0 (SPSS Inc., Chicago, IL, USA). Concerning
MWP and ABI, significance between baseline and at 2 years
was tested using the t-test for paired samples. Between-
group comparisons were performed using the t-test for
independent samples. For analysis of HRQL parameters,
non-parametric tests were used (Wilcoxon signed rank test
and ManneWhitney U test). The magnitude of the change in
HRQL variables was estimated using effect size calculations
(ES Z difference in mean values between baseline and 2
years per SD at baseline). Cohen’s criteria10 for interpreting
ES were applied (small Z 0.2e0.5, moderate Z 0.5e0.8
and large >0.8). Correlation analysis (Pearson) was per-
formed between SF-36 subscales and MWP at baseline.
Logistic regression was used for comparison of minimisation
variables versus MWP.
A per-protocol analysis was also performed, excluding
patients in both groups not receiving allocated randomised
treatment.
Figure 1 Diagram showing flow of randomised patients through trial.
Figure 2 Health related quality of life (HRQL), assessed with
SF-36, in patient group at baseline as compared to age and
gender-matched population data (reference group).
Randomised Trial in Intermittent Claudication 223Results are presented as means  SD (most variables) or
median values (subjectively reported walking distance).
Statistical significance was determined at p < 0.05.
Results
Inclusion and baseline data
After inclusion of nearly 200 patients overall in the present
study, long delays in invasive treatment for IC patients had
become increasingly common due to economic constraints.
A study from our group at that time demonstrated >15%
improvement in MWP by invasive versus control treatment.14
With a 15% difference (10 W) in MWP between the INV and
NON groups at 2 years, a sample size of 200 patients with
75e80% evaluable at 2 years would allow a power of 77% with
beta 0.05. Patient inclusion was stopped at this point.
Fig. 1 shows the flow of randomised patients. Approxi-
mately 600 patients were estimated to have been referred
for IC during a 7-year inclusion period ending in January
2002. The studied sample of 130 patients suggested that
25% had either incorrect diagnosis, other medical condition
limiting MWP or did not seek treatment for IC; 18% were
85 years; 11% had subcritical ischaemia, aortic thrombosis
or were unable to work due to IC and 3% had multiple
previous reconstructions. The remaining 250e260 patients
were eligible for inclusion. In the sample of 130 patients,
14% did not consent and 5%, based on duplex ultrasound,
needed reconstruction below the tibioperoneal trunk. As
many as 201 patients, constituting approximately 60% of all
referred patients 85 years of age with verified IC limiting
MWP, were finally randomised in the study. As expected,
baseline demographic and clinical data were nearly iden-
tical in the two groups (Table 1). Nearly one-fifth (17%) inthe study population were categorised as Rutherford cate-
gory 1 (mild claudication), 55% as category 2 (moderate
claudication) and 28% as category 3 (severe claudication).
Baseline MWP was 66  25 and 67  24 W in the INV and
NON groups, respectively. The median subjectively repor-
ted maximum walking distance was 100 m (20e2000 m) in
the INV group and 100 m (10e500 m) in the NON group.
Logistic regression showed that age, female gender, current
smoking and low ABI were related to MWP. Nearly a third
(30%) had elevated S-cholesterol (>4.5 mmol l1) and
approximately two-thirds of these patients had lipid-
lowering therapy. HRQL was impaired for all SF-36 domains
as compared to age- and gender-matched population data
(Fig. 2).11 The most pronounced differences were noted
regarding parameters quantifying physical performance (PF
and RP) and BP. At baseline, several SF-36 subscales were
related to MWP (correlation coefficients; PF: 0.241, MH:
0.311, RE: 0.307 and VT: 0.225, all significant at the 0.01
level, two-tailed test).
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During the 2 years, seven patients (4%) died, including six
NON- and one INV-group patients (n.s), (Fig. 3). No ampu-
tations were performed. Overall attendance at 6, 12 and
24 months was 85%, 82% and 79%, respectively. Main
reasons for not attending at 24 months were deaths (3.5%)
or dropouts (8%) due to intercurrent disease making
treadmill test and/or HRQL questionnaires impossible or
irrelevant (cancer, stroke or severe cardiovascular condi-
tion). Nearly a tenth (9%) of all patients for unknown
reasons failed to return for outpatient visits. The atten-
dance rate at 24 months was 86% in the INV versus 71% in
the NON group.
In the INV group, 80% received invasive treatment after
a median time of 14 (3e72; interquartile range (IQR)Z 17)
weeks. The reasons for not receiving invasive treatment are
given in Fig. 1. In the INV group, 13 of the crossovers were
according to the study protocol and seven were against. In
the NON group, 91% of the patients were treated according
to randomisation, all nine crossovers were according to
protocol as they were treated invasively because of dete-
rioration (worsening claudication, n Z 8 and subcritical
limb ischaemia, n Z 1).
Thirty-nine procedures (49%) were supra- and 41 (51%)
infrainguinal (Table 2) and overall, 53% of all procedures
were surgical. ABI improved (p Z 0.001) in the
INV (þ0.19  0.2) versus the NON group. Twenty-one re-
interventions were performed on nine patients during
follow-up. At 24months, 70% of the INV patients had a patent
vascular reconstruction (Fig. 4). The change in MWP at 2
years in the INV versus the NON group failed to reach
significance, (pZ 0.104, Fig. 5). Results regarding MWP at 6
and 12 months were similar to the 24 months’ findings. The
NON group patients receiving invasive treatment all had an
MWP <60 W at baseline. Two-year results in these nine
patients were similar to those obtained in the INV group
(MWP change þ 11  28 W).
The change from baseline to 24 months in the per-
protocol analysis of MWP was significant (10 W vs. 0.6 W
improvement in the INV vs. NON group, p Z 0.041).Figure 3 KaplaneMeier survival curves in relation to treat-
ment group (n.s).Changes in HRQOL
The INV group improved significantly compared with the
NON group regarding RP (p < 0.05) and BP (p < 0.01) with
moderate to large effects regarding RP and BP, respec-
tively, in the INV group. Fig. 6 shows effect sizes for each
domain by treatment group.
Smoking habits and additional analyses
On inclusion and 24 months, respectively, 41% and 23% in
the invasive group and 43% and 25% in the non-invasive
group stated current smoking. Measuring u-cotinine, 55%
and 51% were nicotine users at 24 months, respectively.
MWP results were not related to u-cotinine levels.
On inclusion, walking performance on the treadmill was
limited by claudication pain in all patients. At 24 months,
we found a difference in reasons for stopping the treadmill
test between the two treatment groups. The NON group
most often (56%) stopped because of intolerable claudica-
tion, whereas the most common cause (59%) in the INV
group was general fatigue (p Z 0.042), (Fig. 7).
Discussion
In this ‘real life’ type of study, we randomised patients
based on clinical examination and arterial duplex, which
reflects our clinical routines regarding the initial choice of
treatment strategy for claudicants. Although our calcula-
tions of referrals and exclusion rates have some degree of
uncertainty, as they are based on analysis of smaller
samples and an assumption of constant referral patterns
over the years, we opine it is safe to say that we included
a large proportion of all IC patients referred to us. In this
unselected patient group, the primary invasive treatment
strategy did not significantly improve MWP, the primary
outcome variable, but resulted in moderate to large effects
on SF-36 domains BP and RP (i.e., the ability to perform
daily activities). The observed improvement of MWP in the
INV group was lower than expected, leading to only 42%
power to demonstrate significantly improved MWP. Lacking
a clear definition of the clinical significance of the size of
a change in SF-36 domain scores, effect sizes (ES)10 were
calculated to assist in interpreting such changes. Effect size
estimates have been shown to correspond to patient- and
clinician-based assessments of clinical significance.12 We
observed a 91% compliance rate with the primary non-
invasive strategy. Invasive treatment in the 9% NON group
patients who deteriorated was successful. The primary
invasive treatment strategy was completed in 80% of the
INV-group patients. Six patients in the INV group were
treated non-invasively due to the development of increased
risk (myocardial infarction, n Z 1; severe angina pectoris,
nZ 3; heart failure, nZ 1; and renal failure, nZ 1) after
randomisation, reflecting the atherosclerotic burden in
these patients. This could be a potential study bias. More-
over, as patency was determined based on indirect
measures, according to our clinical routine, these values
may have some degree of uncertainty.
Two4 previous randomised controlled studies evaluated
invasive treatment including open surgery for IC. Lundgren
Table 2 Invasive treatment group: surgical procedures and compliance.
Type of procedure No of procedure
Total number of interventions 80
Angioplasty iliac artery 25
Aorto/iliacofemoral bypass 6
Axilloefemoral bypass 1
Femoroefemoral bypass 6
Surgical exploration only 1
Procedures above inguinal ligament, total 39
Angioplasty superficial femoral artery 12
Angioplasty poplitaeal artery 1
Endarterectomy  patch femoral artery/profundaplasty 3
Femoropopliteal bypass above knee 14
Femoropopliteal bypass below knee 8
Vein bypass distal to the popliteal artery 3
Procedures below inguinal ligament, total 41
Randomised Trial in Intermittent Claudication 225et al.,13 in a study from Gothenburg, 1989, demonstrated
improved walking capacity with open vascular reconstruc-
tion versus physical training. In 2001, we published a study
of invasive treatment versus supervised exercise training
versus controls receiving only general training advice,14,15
showing benefit for invasive treatment regarding walking
performance and HRQL. The effects of invasive treatment
were moderate.
In selected IC patients suitable for angioplasty, there are
recent randomised studies comparing results of BMT with
and without endovascular intervention, respectively. In the
Oslo balloon angioplasty versus conservative treatment
strategy (OBACT) trial,16 a benefit of angioplasty regarding
physiological parameters was demonstrated. Out of 434 IC
patients, 56 (13%) were finally randomised. The improve-
ment by angioplasty in this selected group of patients was
moderate.
In the multicentre mild-to-moderate intermittent clau-
dication (MIMIC) trial,17 the adjuvant benefit of angioplastyFigure 4 Cumulative patency (KaplaneMeier) in the INV
group during follow-up. Values represent indirect measures of
patency (ABI improvement >0.1).in addition to BMT and supervised exercise training were
studied in selected patients suitable for angioplasty, in two
separate trials (aorto-iliac and femoropopliteal disease).
Only one-tenth of 1401 screened IC patients were finally
eligible, mainly because of patient refusal and selective
inclusion criteria. Of these, 127 patients were enrolled in
the studies. The investigators showed moderate improve-
ment by invasive treatment in physiological parameters in
both trials. HRQL improvement was shown in the aorto-iliac
but not in the femoropopliteal trial.
In 2008, Spronk et al.18 compared endovascular inter-
vention with a hospital-based supervised exercise training
programme and found no difference regarding walking
performance or HRQL at 12 months.
In comparison, our study differs in some aspects. Due to
our design, allowing lesions anywhere in arterial segments
from the aorta to the tibioperoneal trunk and surgical and/
or endovascular invasive treatment, we studied the effects
of revascularisation, irrespective of the technique used and
randomised a significant proportion of all IC patients
referred to us. Controlled studies of revascularisation for IC
are often hampered by poor recruitment rates,19 making
performance of studies as well as generalisation of theFigure 5 Results regarding maximal walking performance
(MWP) in the INV versus NON group from baseline to 24 months.
Figure 6 Effect sizes (ES) calculated between baseline and
24-months for INV and NON patients for the 8 SF-36 subscales.
Cohen’s criteria for ES: 0,0e0,2 Z trivial; 0,2e0,5 Z small;
0,5e0,8 Z moderate; >0,8 Z large ) Significant between-
group difference between baseline and 24-months (Man-
neWhitney U). # Significant improvement between baseline
and 24-months (Wilcoxon Signed Rank Test).
226 J. Nordanstig et al.results difficult. Our aim was to compare the outcome of
two different primary treatment strategies in unselected
patients.
Maximum walking performance assessed in any treadmill
protocol is subject to biases and may not entirely reflect
daily walking performance. There could be a difference
between the ability to perform daily physical activities and
the measured performance on a treadmill test. A patient
with poor blood flow to the lower limb(s) could have poor
performance on the treadmill but might, in theory, be able
to walk long distances on flat surfaces slowly. We used
a graded treadmill test as primary outcome parameter. This
test correlates significantly to HRQL,20 and graded tests are
highly reproducible and reported to be superior to constant
treadmill tests.21 On inclusion, all patients were limited byFigure 7 Reasons for stopping on treadmill test at 24 months follo
noted between groups regarding the distribution of reasons for enclaudication pain at treadmill test. During follow-up,
invasively treated patients often stopped the treadmill test
due to general fatigue. Hence, their claudication pain may
have been abolished by invasive treatment but other
conditions, for example cardiac or respiratory failure, may
have been unmasked, limiting MWP.
It can be argued that supervised exercise training is
more efficient than non-supervised training.22 In this study,
we chose non-supervised training, as we previously
observed poor compliance to our supervised programme
with no significant effect versus exercise training advice.14
Exercise training is known to improve walking performance
but improvement may disappear, if the patient stops
training. Moreover, strong evidence for extra benefit,
regarding HRQL, for supervised versus non-supervised
training is lacking.22
HRQL was assessed using a generic instrument. Several
studies highlight the importance of using both a generic and
a disease-specific instrument, as generic instruments may
be less sensitive for detecting small but clinically important
differences.23 Nevertheless, we were able to show signifi-
cant HRQL improvement indicating important effects over
time by invasive treatment. Attendance rate at follow-up
was less in the NON group and although we have no data to
suggest this, we cannot entirely exclude that the unat-
tending subjects performed worse, influencing the results.
In summary, this study in unselected IC patients failed to
show significantly improved MWP with a primary invasive
versus a primary non-invasive treatment strategy. Invasive
treatment resulted in moderate to large positive HRQL
effects regarding physical role function and pain. At the
same time, the primary non-invasive treatment strategy
had a low (9%) crossover rate occurring only in patients with
baseline MWP < 60 W. Although our data shows HRQL
advantages with invasive treatment, this has to be evalu-
ated further, as HRQL was a secondary end point in this
study.
In conclusion, the present results give some further
support for improved HRQL by invasive treatment but,
overall, there is still only a limited evidence base for
invasive treatment of IC patients.w-up, according to treatment group. Significant difference was
ding treadmill test (p Z 0.042).
Randomised Trial in Intermittent Claudication 227Conflict of Interest
None.Acknowledgements/Funding
Swedish Heart-Lung Foundation.
Swedish Federal Government under the LUA/ALF
agreement.
Region Va¨stra Go¨taland (KVG).
Christer Drott, MD, PhD, Bora˚s Hospital, Vascular Surgery
Unit.
Bengt Lindberg, MD, PhD, Kunga¨lv Hospital, Vascular
Surgery Unit.References
1 Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O,
Andersson B, Persson E, et al. A population-based study of
peripheral arterial disease with special focus on critical limb
ischemia and sex differences. J Vasc Surg 2007;45:1185e91.
2 Ouriel K. Peripheral arterial disease. Lancet 2001;358:
1257e64.
3 Dormandy J, Heeck L, Vig S. The natural history of claudication:
risk to life and limb. Semin Vasc Surg 1999;12(2):123e37.
4 Peripheral arterial disease e Diagnosis and treatment.
Systematic review. Sweden: The Swedish Council on Technology
Assessment in Health Care; 2007.
5 Duran NE, Duran I, Gu¨rel E, Gundu¨z S, Go¨l G, Biteker M, et al.
Coronary artery disease in patients with peripheral artery
disease. Heart Lung 2010;39(2):116e20.
6 Raghunathan A, Rapp JH, Littooy F, Santilli S, Krupski WC,
Ward HB, et al. CARP Investigators. Postoperative outcomes for
patients undergoing elective revascularization for critical limb
ischaemia and intermittent claudication: a subanalysis of the
coronary artery revascularization prophylaxis (CARP) trial.
J Vasc Surg 2006;43(6):1175e82.
7 The Swedish National Registry for Vascular Surgery, Swedvasc.
8 Pocock SJ, Simon R. Sequential treatment assignment with
balancing for prognostic factors in the controlled clinical trial.
Biometrics 1975;31:103e15.
9 Klevsga˚rd R, Fro¨berg B-L, Risberg B. Nottingham health profile
and short-form 36 health survey questionnaires in patients with
chronic lower limb ischaemia: before and after revasculariza-
tion. J Vasc Surg 2002;36:310e7.
10 Cohen J. Statistical power analysis for the behavioural
sciences. London/New York: Academic Press; 1977.
11 Sullivan M, Karlsson J, Taft C. SF-36 Health Survey: Swedish
manual and interpretion guide. 2nd ed. Gothenburg: Sahl-
grenska University Hospital; 2002.12 Norman GR, Sloan JA, Wyrwich KW. Interpretion of changes in
health-related quality of life. Med Care 2003;41:582e92.
13 Lundgren F, Dahllo¨f A-G, Lundholm K, Scherste´n T, Volkman R.
Intermittent claudication e surgical reconstruction or physical
training? e a prospective randomised trial of treatment effi-
ciency. Ann Surg 1989;209:346e55.
14 Gelin J, Jivega˚rd L, Taft C, Karlsson J, Sullivan M, Dahllo¨f A-G,
et al. Treatment efficacy of intermittent claudication by
surgical intervention, supervised physical exercise training
compared to no treatment in unselected randomised patients I:
one year results of functional and physiological improvements.
Eur J Vasc Endovasc Surg 2001;22:107e13.
15 Taft C, Karlsson J, Gelin J, Jivega˚rd L, Sandstro¨m R,
Arfvidsson B, et al. Treatment efficacy of intermittent claudi-
cation by invasive therapy, supervised physical exercise training
compared to no treatment in unselected randomised patients II:
one-year results of health-related quality of life. Eur J Vasc
Endovasc Surg 2001;22:114e23.
16 Nylænde M, Abdelnoor M, Stranden E, Morken B, Sandbæk G,
Risum Ø, et al. The Oslo balloon angioplasty versus conservative
treatment study (OBACT) e the 2-years results of a single
centre, prospective, randomised study in patients with inter-
mittent claudication. Eur J Vasc Endovasc Surg 2007;33:3e12.
17 The Mimic Trial Participants. The Adjuvant Benefit of angio-
plasty in patients with mild to moderate intermittent claudi-
cation (MIMIC) managed by supervised exercise, smoking
cessation advice and best medical therapy: results from two
randomised trials for stenotic femoropopliteal and aortoiliac
arterial disease. Eur J Vasc Endovasc Surg 2008;36:680e8.
18 Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PMT,
Hunink MG. Cost-effectiveness of endovascular revascularisa-
tion compared to supervised hospital-based exercise training in
patients with intermittent claudication: a randomised
controlled trial. J Vasc Surg 2008;48:1472e80.
19 Campbell WB, Birchley DW. What is the place for surgery in
intermittent claudication? Eur J Vasc Endovasc Surg 2010;39:
745e6.
20 Arfvidsson B, Karlsson J, Dahllo¨f AG, Lundholm K, Sullivan M.
The impact of intermittent claudication on quality of life
evaluated by the sickness impact profile technique. Eur J Clin
Invest 1993;23(11):741e5.
21 Nicolaı¨ SPA, Viechtbauer MS, Kruidenier LM, Candel MJJM,
Prins MH, Teijink JAW. Reliability of treadmill testing in
peripheral arterial disease: a meta-regression analysis. J Vasc
Surg 2009;50:322e9.
22 Bendermacher BLW, Willigendael EM, Teijink JAW, Prins MH.
Supervised exercise therapy versus non-supervised
exercise therapy for intermittent claudication. Cochrane
Database Syst Rev 2006;(Issue 2). doi:10.1002/14651858. Art
No.: CD005263CD005263.pub2.
23 Metha T, Venkata Subramaniam A, Chetter I, McCollum P.
Assessing the validity and responsiveness of disease-specific
quality of life instruments in intermittent claudication. Eur J
Vasc Endovasc Surg 2006;31:46e52.
